Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly(A) binding protein cytoplasmic 1 pseudogene 2 (PABPC1P2) is a noncoding pseudogene in humans, classified as a member of the poly(A) binding protein family but lacking evidence of protein-coding ability and functional protein product. The name suggests similarity to poly(A) binding proteins involved in mRNA stabilization, translation, and post-transcriptional regulation, but PABPC1P2 itself does not perform these functions. It is often listed alongside the aliases PABP2 and PABP4, which refer to functional poly(A) binding proteins—such as PABPC4 (involved in erythroid cell development) and PABPN1 (polyadenylate-binding nuclear protein 1 associated with mRNA processing and oculopharyngeal muscular dystrophy)—but PABPC1P2 should not be confused with these. Pseudogenes like PABPC1P2 are generally not considered direct therapeutic targets, though some may exert regulatory roles by acting as microRNA decoys or influencing gene expression indirectly in limited contexts.
None applicable, since the gene does not encode a functional protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly(A) binding protein cytoplasmic 1 pseudogene 2 (PABPC1P2).